By Professor Michael Leonard Friedlander

Journal articles

Hacker NF; Friedlander ML, 2004, 'Treatment of recurrent ovarian cancer', Chang Gung Medical Journal, 27, pp. 570 - 577, http://www.sciencedirect.com/science/article/B6WVB-4DVW7KP-2Y0/2/9a983bdc3c2e8ebecc9287dafa401635

Friedlander M; Hogg R; Phillips KA, 2003, 'Management of women at increased genetic risk of ovarian cancer', Cancer Forum, 27, pp. 151 - 156

Scott CI; Iorgulescu DG; Thorne HJ; Henderson MA; Phillips KA; Sambrook J; Chenevix-Trench G; Friedlander M; Baxter N; Evans G; Waring P; Clouston D, 2003, 'Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy', Clinical Genetics, 64, pp. 111 - 121, http://dx.doi.org/10.1034/j.1399-0004.2003.00097.x

Hogg R; Friedlander M, 2003, 'Role of systemic chemotherapy in metastatic cervical cancer', Expert Review of Anticancer Therapy, 3, pp. 234 - 240, http://dx.doi.org/10.1586/14737140.3.2.234

Tiller K; Meiser B; Reeson E; Tucker M; Andrews L; Gaff C; Kirk J; Phillips KA; Friedlander ML, 2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecological Cancer, 13, pp. 15 - 22

Tiller K; Meiser B; Reeson E; Tucker M; Andrews L; Gaff C; Kirk J; Phillips KA; Friedlander M, 2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecologic Cancer, 13, pp. 15 - 22, http://dx.doi.org/10.1136/ijgc-00009577-200301000-00003

Friedlander ML; Jones R; Ryan M, 2003, 'Carboplatin hypersentivity reactions: re-treatment with cisplatin desensitisation', Gynecologic Oncology, 89, pp. 112 - 115

Friedlander ML; Thewes B, 2003, 'Counting the costs of treatment: the reporductive and gynaecological consequences of adjuvant therapy in young women with breast cancer', Internal Medicine Journal, 33, pp. 372 - 379

Apicella C; Andrews L; Hodgson SV; Fisher SA; Lewis CM; Solomon E; Tucker K; Friedlander ML; Bankier A; Southey MC; Venter DJ; Hopper JL, 2003, 'Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defines personal and family history in an Ashkenazi Jewish woman LAMBDA', Breast Cancer Research, 5, pp. 206 - 216

Thewes B; Meiser B; Rickard J; Friedlander ML, 2003, 'The fertility and menopause-related information needs of younger women with a diagnosis of breast cancer', Psycho - Oncology, 12, pp. 500 - 511

Hogg R; Friedlander M, 2002, 'Management of embryonal carcinoma of the ovary', CME Journal of Gynecologic Oncology, 7, pp. 234 - 237

Friedlander ML, 2002, 'Guidelines for the treatment of recurrent and metastatic cervical cancer', Oncologist, 7, pp. 342 - 347

Meiser B; Butow P; Friedlander ML; Barratt AJ; Schnieden V, 2002, 'Psychological impact of genetic testing in women from high risk breast cancer families', European Journal of Cancer, 38, pp. 2025 - 2031

Tiller K; Meiser B; Butow P; Clifton M; Thewes B, 2002, 'Psychological Impact of Prophylactic Oophorectomy in Women at Increased Risk of Developing Ovarian Cancer: A Prospective Study', Gynecologic Oncology, 86, pp. 212 - 219

Leary JA; Friedlander ML, 2002, 'The molecular genetics of epithelial ovarian cancer', Current Medical Literature Gynaecology and Obstetrics, 8, pp. 1 - 7

Marx GM; Friedlander ML, 2001, 'Drug toxicity prevention and management', CME Journal of Gynecologic Oncology, 6, pp. 29 - 33

Yang JL; Friedlander ML, 2001, 'Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect', Lancet, 357, pp. 1767 - 1768, http://dx.doi.org/10.1016/S0140-6736(00)04892-3

Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D; Abdi E; Kotasek D; Beadle G; Friedlander M; Anton A; Aranda E; Murillo E; Nogueira M; Balli M; De Lena M; Lopez M; Luporini G; Micheletti E; Morrica B; Tordiglione M; Breitbach GP; Dornhoff W; Klinkenstein C; Villena C; Wilken H; Cervek J; Chacòn R; Estévez R; Mickiewicz E; Muro H; Damianov D; Donat D; Vuletic L; Gershanovich MNN; Ghilezan N; Hegg R; Jassem J; Pawlicki M; Ramlau C; Siedlecki P; Kocak I; Korec S; Muse IM; Nagykàlnai T; Perenyi L; Pinter T; Vallejos CS; Vogel C, 2001, 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19, pp. 943 - 953, http://dx.doi.org/10.1200/JCO.2001.19.4.943

Marx GM; Friedlander ML; Hacker NF, 2001, 'Cytotoxic drug treatment of vulval and vaginal cancer', CME Journal of Gynecologic Oncology, 6, pp. 67 - 72

Bahar AY; Taylor PC; Andrews L; Proos A; Tucker K; Burnett L; Friedlander ML; Buckley MF, 2001, 'Genetic Analysis of Breast, Ovarian and Colorectal Cancer in the Sydney Ashkenazi Jewish Population', Cancer, pp. 440 - 445

Pribill I; Speiser P; Leary JA; Leodolter S; Hacker NF; Friedlander ML; Birnbaum D; Zeillinger R; Krainer M, 2001, 'High Frequency of Allelic Imbalance at Regions of Chromosome 8p in Ovarian Carcinoma', Cancer, 129, pp. 23 - 29

Evans VE; Vockler C; Friedlander ML; Walsh B; Willcox MD, 2001, 'Lacroglobin in Human Tears, a Potential Marker for Cancer', Clinical and Experimental Ophthalmology, pp. 161 - 163

Evans VE; Vockler C; Friedlander ML; Walsh B; Willcox MD, 2001, 'Lacryglobin in human tears, a potential marker for cancer', Clinical and Experimental Ophthalmology, pp. 161 - 163

Bahar A; Taylor P; Andrews L; Proos AL; Burnett L; Tucker K; Friedlander M; Buckley M, 2001, 'The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data', Cancer, 92, pp. 440 - 445

Yang JL; Friedlander ML, 2001, 'Therapeutic Benefit of Nifedipine in Metastatic Colon Cancer with DNA Mismatch Repair Gene Defect: Clinical Observation and Supportive Laboratory Evidence', Lancet, pp. 1767 - 1768

Vergote I; Rustin GJS; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MKB; Friedlander M; Jakobsen A; Vermorken JB, 2000, 'Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer] [3]', Journal of the National Cancer Institute, 92, pp. 1534 - 1535

Meiser B; Butow P; Barratt A; Friedlander M; Kirk J; Gaff C; Haan E; Aittomäki K; Tucker K, 2000, 'Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer', Breast Cancer Research and Treatment, 59, pp. 101 - 111, http://dx.doi.org/10.1023/A:1006330631832

Rapley EA; Crockford GP; Teare D; Biggs P; Seal S; Barfoot R; Edwards S; Hamoudi R; Heimdal K; Fosså SD; Tucker K; Donald J; Collins F; Friedlander M; Hogg D; Goss P; Heidenreich A; Ormiston W; Daly PA; Forman D; Oliver RTD; Leahy M; Huddart R; Cooper CS; Bodmer JG; Easton DF; Stratton MR; Bishop DT, 2000, 'Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours', Nature Genetics, 24, pp. 197 - 200, http://dx.doi.org/10.1038/72877

Faulkner SW; Leigh DA; Oosterhuis JW; Roelofs H; Looijenga LHJ; Friedlander ML, 2000, 'Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: Evidence suggestive of the linear progression model', British Journal of Cancer, 83, pp. 729 - 736, http://dx.doi.org/10.1054/bjoc.2000.1334

Meiser B; Butow P; Friedlander M; Schnieden V; Gattas M; Kirk J; Suthers G; Haan E; Tucker K, 2000, 'Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer', Journal of Clinical Oncology, 18, pp. 2250 - 2257, http://dx.doi.org/10.1200/JCO.2000.18.11.2250

Faulkner SW; Friedlander ML, 2000, 'Microsatellite instability in germ cell tumors of the testis and ovary', Gynecologic Oncology, 79, pp. 38 - 43, http://dx.doi.org/10.1006/gyno.2000.5906

Faulkner SW; Friedlander ML, 2000, 'Molecular genetic analysis of malignant ovarian germ cell tumors', Gynecologic Oncology, 77, pp. 283 - 288, http://dx.doi.org/10.1006/gyno.2000.5762

Sanson-Fisher R; Girgis A; Boyes A; Bonevski B; Burton L; Cook P; Ackland S; Baker R; Berry M; Biggs J; Bishop J; Bokey L; Burnard A; Clingan P; Cregan P; Dunn S; Friedlander M; Goulston K; Hacker N; Kearsley J; Langlands A; Levi J; Moylan E; Stewart J; Tattersall M, 2000, 'The unmet supportive care needs of patients with cancer', Cancer, 88, pp. 225 - 236, http://dx.doi.org/10.1002/(sici)1097-0142(20000101)88:1<226::aid-cncr30>3.0.co;2-p

Marsden DE; Friedlander ML; Hacker NF, 2000, 'Current management of Epithelial Ovarian Carcinoma: A Review', Seminars in Surgical Oncology, 19, pp. 11 - 19

Bonevski B; Sanson-Fisher R; Girgis A; Burton L; Cook P; Boyes AW; Ackland S; Baker RW; Berry M; Biggs J, 2000, 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, 88, pp. 217 - 225

Friedlander ML, 1999, 'Multivariate prognostic models in ovarian cancer', CME Journal of Gynecologic Oncology, 4, pp. 256 - 258

Friedlander ML, 1999, 'Surgical stage, ascites, peritoneal cytology, tumour spillage, dense adherence', CME Journal of Gynecologic Oncology, 4, pp. 38 - 40

Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K, 1999, 'Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer', Gynecologic Oncology, 75, pp. 122 - 129, http://dx.doi.org/10.1006/gyno.1999.5544

Links MJ; Watson SR; Lethlean K; Aherne W; Kirsten F; Clarke SP; Law MG; Friedlander ML; Galettis P; Mckeage M, 1999, 'Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin', Cancer Investigation, 17, pp. 479 - 485

Friedlander M, 1998, 'A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer', Annals of Oncology, 9, pp. 1343 - 1345, http://dx.doi.org/10.1023/A:1008469212268

Friedlander ML, 1998, 'Prognostic factors and tumour markers in ovarian teratomas', CME Journal of Gynecologic Oncology, 3, pp. 177 - 180

Friedlander ML, 1998, 'Prognostic factors in ovarian cancer', Seminars in Oncology, 25, pp. 305 - 314

Kefford R; Tucker K; Friedlander M; Kirk J, 1998, 'Cancer in the family. Part 2.', Australian family physician, 27, pp. 40 - 44

Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J, 1998, 'Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer', Journal of Clinical Oncology, 16, pp. 1948 - 1953, http://dx.doi.org/10.1200/JCO.1998.16.5.1948

Hacker NF; Bancher-Todesca D; Williams KL; Neunteufel W; Friedlander ML, 1998, 'Influence of post operative treatment on survival in patients with uterine papillary serous carcinoma', Gynecologic Oncology, pp. 344 - 347

Links MJ; Ribeiro JC; Jackson P; Friedlander ML; Russell PJ, 1998, 'Regulation and deregulation of G2 checkpoint proteins with cisplatin', Anticancer Research, 18, pp. 4057 - 4066

Beller E; Tattersall M; Lumley T; Levi J; Dalley D; Olver I; Page J; Abdi E; Wynne C; Friedlander M; Boadle D; Wheeler H; Margrie S; Simes RJ, 1997, 'Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial', Annals of Oncology, 8, pp. 277 - 283, http://dx.doi.org/10.1023/A:1008291825695

Friedlander M, 1997, 'A menopausal woman with a history of breast cancer: Should she receive HRT?', Modern Medicine of Australia, 40, pp. 164 - 165

Michael M; Bishop JF; Levi JA; Bell DR; Zalcberg JR; Friedlander ML; Olver LN; Smith JG; Toner GC, 1997, 'Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy', Medical Journal of Australia, 166, pp. 520 - 523, http://dx.doi.org/10.5694/j.1326-5377.1997.tb123243.x

Kefford R; Tucker K; Friedlander M; Kirk J, 1997, 'Cancer in the family. Guidelines for general practice.', Australian family physician, 26, pp. 545 - 549

Back to profile page